Tumor-induced immunosuppression;Immunité antitumorale et tolérance immunitaire

Annales de Biologie Clinique

Volumn 60, Issue 2, 2002, Pages 143-152

  Paul, S ^a   Calmels, B ^a   Regulier E ^a  

^a TRANSGENE S A   (France)

Author keywords

Apoptosis; Immunity; Immunosuppression; Tolerance; Tumor

Indexed keywords

AUTOANTIGEN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER INVASION; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; EFFECTOR CELL; HOST CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; LYMPHOCYTE PROLIFERATION; REVIEW; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; ANIMAL; APOPTOSIS; ARTICLE; BIOLOGICAL MODEL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; NEOPLASM;

ANIMALS; APOPTOSIS; HUMANS; IMMUNE TOLERANCE; MODELS, IMMUNOLOGICAL; NEOPLASMS;

EID: 0036217982     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Tumor-induced immune dysfunction
2. Human tumor antigens for cancer vaccine development
3. The binding and lysis of target cells by cytotoxic lymphocytes: Molecular and cellular aspects
4. Cytokine-induced cytotoxic function expressed by lymphocytes of the innate immune system: Distinguishing characteristics of NK and LAK based on functional and molecular markers
5. Tumor cell recognition by lymphocytes: Is the MHC always essential?
6. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis
7. Cancer-induced defective cytotoxic T lymphocyte effector function: Another mechanism how antigenic tumors escape immune-mediated killing
8. HLA class I expression on human cancer cells. Implications for effective immunotherapy
9. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
10. Potential strategies utilised by papillomavirus to evade host immunity
11. T cell defined tumor antigens
12. How tumors escape immune destruction and what we can do about it
13. The diversity of T-cell co-stimulation in the induction of antitumor immunity
14. Dendritic cells in cancer immunotherapy
15. Dendritic cells: A link between innate and adaptive immunity
16. + T-helper and a T-killer cell
17. + T cells
18. + IFN-gamma-producing T cells from tumor-infiltrating lymphocytes
19. Creating and engineering human antibodies for immunotherapy
20. Monocyte/macrophages as effector cells in cancer immunotherapy
21. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma-long-lasting, complete remissions can be induced
22. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
23. B cells inhibit induction of T cell-dependent tumor immunity
24. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice
25. T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28
26. Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies
27. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors
28. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
29. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas
30. The makings of a tumor rejection antigen
31. Lewis blood group and CEA related antigens; coexpressed cell-cell adhesion molecules with roles in the biological progression and dissemination of tumours
32. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination
33. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte
34. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats
35. Immunogenicity of apoptotic cells in vivo: Role of antigen load, antigen-presenting cells, and cytokines
36. Macrophage suppression of T cell activation: A potential mechanism of peripheral tolerance
37. Immunomodulatory effects of transforming growth factor-beta on T lymphocytes. Induction of CD8 expression in the CTLL-2 cell line and in normal thymocytes
38. Lack of evidence for an immunosuppressive role for MUC1
39. Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis?
40. Tumor gangliosides inhibit the tumor-specific immune response
41. The host-tumor immune conflict: From immunosuppression to resistance and destruction
42. IL6 and IFN-gamma regulation of IL10 production by human colon carcinoma cells
43. Role of transforming growth factor beta in human disease
44. Tumour-associated macrophages (TAMS): Disordered function, immune suppression and progressive tumour growth
45. Histamine protects T cells and natural killer cells against oxidative stress
46. Tumour-induced suppression of immune response and its correction
47. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL12 and endothelin-1
48. A matter of life and cell death
49. Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes
50. Apoptosis control by death and decoy receptors
51. Caspases: Enemies within
52. Bcl-2 gene promotes haematoopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
53. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2
54. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
55. Molecular and cellular mechanisms regulating T and B cell apoptosis through Fas/FasL interaction
56. Somatic Fas mutations in non-Hodgkin's lymphoma: Association with extranodal disease and autoimmunity
57. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells
58. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas
59. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
60. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
61. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?
62. Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back
63. The central role of CD4(+) T cells in the antitumor immune response
64. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1
65. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors
66. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors
67. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein
68. IAP family proteins-suppressors of apoptosis
69. A novel anti-apoptosis gene, surviving, expressed in cancer and lymphoma
70. The Bcl-2 protein family: Arbiters of cell survival
71. Two CD95 (APO-1/Fas) signaling pathways
72. In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis
73. Bax suppresses tumorigenesis and stimulates apoptosis in vivo
74. Cancer immunotherapy: New approaches
75. The hallmarks of cancer